FDA: Pfizer Should Update Label, Perform Meta-Analysis on Chantix
The FDA is asking Pfizer to perform a meta-analysis of existing clinical data on Chantix to evaluate the drug’s cardiovascular safety after concerns that it may increase heart attack risk.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.